ATAI shares surge on report of Eli Lilly buyout worth about $2.8 billion, lifting sympathy momentum for Compass Pathways
Pre-market trading chatter linked Eli Lilly to a reported $2.8 billion acquisition of ATAI. Stocks of Compass Pathways (CMPS) also moved higher as traders appeared to connect the deal to the broader psychedelic and neuropsychiatry space.